Vida Ventures, a next-generation life sciences investment firm, and Leaps by Bayer, a venture capital company, led a $175m funding round in Affini-T Therapeutics, a developer of therapeutics platform, with participation from Humboldt Fund, The Parker Institute for Cancer Immunotherapy, Catalio Capital Management, Agent Capital, Alexandria Venture Investments, Erasca Ventures and Fred Hutchinson Cancer Research Center. “By targeting oncogenic drivers like mutated KRAS, we strike at the core genetic mutations that enable tumors to grow and spread. Our differentiated platform combines highly active TCRs with unique synthetic biology, allowing us to pioneer novel therapeutic approaches intended to eradicate solid tumors. With proven management, an unparalleled founding team of scientific innovators and leaders in immunology and cellular engineering, we look forward to bringing life-changing medicines to patients in need," Jak Knowles, Affini-T Therapeutics Co-Founder, President and CEO.